title: Pharmacological characteristics of zolpidem-induced catalepsy in the rat.
abstract: Zolpidem is a non-benzodiazepine hypnotic drug acting preferentially at α1-containing GABAA receptors expressed in various parts of the brain, including the basal ganglia. The aim of the present study was to provide preliminary characteristics of zolpidem-induced catalepsy in Wistar rats. Zolpidem (2.5-10.0mg/kg), but not diazepam and midazolam, produced dose-dependent cataleptic responses in the bar test, which were similar to those produced by a reference antipsychotic drug, haloperidol. Zolpidem-induced catalepsy was abolished by a benzodiazepine site antagonist, flumazenil (5.0mg/kg), D2/3 receptor agonist, quinpirole (1.0mg/kg), and a non-competitive NMDA receptor antagonist, MK-801 (0.1mg/kg), but not by a non-selective opioid receptor antagonist, naltrexone (3.0mg/kg). The present results indicate that systemic injections of zolpidem may produce short-lasting, neuroleptic-like catalepsy in the rat.
authors.affiliation: Department of Pharmacology, Institute of Psychiatry and Neurology, Warsaw, Poland.
authors.forename: Pawel
authors.initials: P
authors.lastname: Mierzejewski
authors.forename: Marcin
authors.initials: M
authors.lastname: Kolaczkowski
authors.forename: Natalia
authors.initials: N
authors.lastname: Nowak
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Korkosz
authors.forename: Anna
authors.initials: A
authors.lastname: Scinska
authors.forename: Halina
authors.initials: H
authors.lastname: Sienkiewicz-Jarosz
authors.forename: Jerzy
authors.initials: J
authors.lastname: Samochowiec
authors.forename: Wojciech
authors.initials: W
authors.lastname: Kostowski
authors.forename: Przemyslaw
authors.initials: P
authors.lastname: Bienkowski
mesh_terms: D000818:Animals; D002375:Catalepsy / Q000139:chemically induced* / Q000503:physiopathology; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005442:Flumazenil / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists / Q000494:pharmacology; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D008297:Male; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists; D011725:Pyridines / Q000009:adverse effects*; D019257:Quinpirole / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017448:Receptors, Dopamine D2 / Q000819:agonists; D050637:Receptors, Dopamine D3 / Q000819:agonists; D011963:Receptors, GABA-A / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D013997:Time Factors; D000077334:Zolpidem
chemical_list: D058787:GABA-A Receptor Antagonists; D006993:Hypnotics and Sedatives; D009292:Narcotic Antagonists; D011725:Pyridines; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D011963:Receptors, GABA-A; D016194:Receptors, N-Methyl-D-Aspartate; D019257:Quinpirole; D005442:Flumazenil; D009271:Naltrexone; D016291:Dizocilpine Maleate; D000077334:Zolpidem
keywords: Catalepsy; Flumazenil; Rat; The GABA(A) receptor; Zolpidem